Evidence that the amount of heparin precipitable fraction is influenced by fibrinogen quality

Chapters in this book

1. Frontmatter I
2. Preface V
3. Contents IX
4. I. A HISTORICAL NOTE
5. Two thousand years of fibrinogen research and evidence for fibrin being the first protein 1
6. II. GENE ANALYSIS
7. Fibrinogen evolution - The structure and evolution of fibrinogen: The coiled coil region 11
8. Absence of gross defect of fibrinogen genes in one patient with congenital afibrinogenemia 23
9. III. FIBRINOGEN-FIBRIN CONVERSION
10. Fibrinogen to fibrin - an overview 33
11. Fibrin - specific monoclonal antibodies are elicited by immunization with a synthetic fibrin-like peptide 43
12. Enhancement of fibrin polymerization by active site - inhibited thrombin 51
13. Peptides released from human fibrinogen by thrombic enzymes 65
14. The analysis of fibrinopeptide release from S--carboxymethylated fibrinogen chains using high-performance liquid chromatography 73
15. Moaification of the fibrin a-chain by dipeptidyl peptidase IV 83
16. IV. FIBRINOGEN-FIBRIN INTERACTION
17. Analysis of composition of soluble fibrinogen/fibrin complexes by differential ultracentrifugation 91
18. Reversible interactions of fibrin and fibrinogen: an ultracentrifugation study 101
19. V. NORMAL FIBRINOGEN VARIANTS
20. Evidence that the amount of heparin precipitable fraction is influenced by fibrinogen quality 113
21. The location of a second in vivo phosphorylation site in the Aa-chain of human fibrinogen 121
22. Evidence that the y chain population of human platelet fibrinogen lacks the y' variant that is present in plasma fibrinogen 133
23. Differences and similarities between human adult and fetal fibrinogen fragments D₁ 147
24. VI. ABNORMAL FIBRINOGEN VARIANTS
25. Functional defects in abnormal fibrinogens 155
26. Study of 10 cases of congenital dysfibrinogenemia: clinical and molecular biological aspects 165
27. Fibrinogens Sydney I and II, a kinetic study of (His¹⁶ )FPA cleavage and its effect on FPB cleavage 185
28. Fibrinogens London I - IV, Manchester, Sydney I and II. Cleavage of fibrinopeptides by thrombin and expression of their polymerisation abnormalities 197
29. Aspects of evaluation of fibrinogen Stony Brook - A defect resulting in failure to release fibrinopeptide A 207
30. Fibrinogen Tokyo II: An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules 213
31. Fibrinogen Milan II: A congenital dysfibrinogenemia with a defective clotting by thrombin, normal clotting by arvin, reptilase and prothrombin-staphy1ocoagulase complex, associated with thrombotic episodes 223
32. Preliminary report concerning two new cases of congenital dysfibrinogenemia (Homburg II and Homburg III) 237
33. The effect of sodium citrate on fibrin polymerisation in patients with liver disease 247
34. VII. FIBRINOGEN DEGRADATION PRODUCTS
35. Studies of the proteolytic fragments of the C-terminal portion of the a-chain of human fibrinogen 257
36. Biodistribution or human fibrinogen-derived peptides in rabbits 271
37. Structure-function studies on a vasoactive pentapeptide derived from plasm in degradation of human fibrin(ogen) 279
38. Purification and characteristics of a vasoactive peptide derived from elastase degradation of human fibrin(ogen) 289
39. Relation of crosslinked to non crosslinked fibrin derivatives in tumor ascites compared to cirrhosis ascites 301
40. VIII. INTERACTION WITH PLASMINOGEN AND ITS ACTIVATOR
41. Study of the interaction between plasminogen and fibrinogen degradation products using immunoenzymological assay 313
42. Fibrin and plasminogen structures involved in the tissue-type plasminogen activator catalyzed activation of plasminogen 323
43. Kinetics of the tissue-type plasminogen activatormediated activation of plasminogen. Influence of CNBr fibrin(ogen) fragment FCB-2 and different forms of plasminogen 331
44. IX. INTERACTION WITH CELLS
45. Structural characterization of the recognition site for platelet receptors on human fibrinogen 345
46. Binding or fibrinogen to ADP-treated platelets: Importance of the Aα-chain 369
47. Inhibition of fibrinogen binding to activated platelets by oligoamines 379
48. Specific interaction between fibrinogen-fibrin and endothelial cells 387
49. Influence of fibrin, fibrinogen and fibrinogen degradation products on cultured endothelial cells 395
50. Interaction of fibrin with malignant melanoma cells in long term culture 405
51. AUTHOR INDEX 413
52. SUBJECT INDEX 415
53. Backmatter 419